PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 62 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR ESMO Open: First Official Impact Factor of 5.329 June 30, 2020 ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... September 10, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Equidacent How we are working with industry to translate research into real... Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... Male Patients with Cancer at Higher Risk of Severe Disease Course...
